Clinical Trials Directory

Trials / Unknown

UnknownNCT03577093

Molecular Mechanisms of microRNA-494 Involving in Cerebral Ischemia

Study on the Molecular Mechanism of miR-494 Mediating Cell Cycle Regulation Following Cerebral Ischemia

Status
Unknown
Phase
Study type
Observational
Enrollment
600 (estimated)
Sponsor
Capital Medical University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers

Summary

We and other investigations suggested that the activation of nerve cell cycle following cerebral ischemia led to neuronal apoptosis, glial cell proliferation and the formation of glial scar.The cyclin-dependent kinases (CDKs) and cyclins jointly promoted the cell cycle progression. Our preliminary clinical trial found a new microRNA-miR-494, which involved in the occurrence of acute ischemic stroke. In our animal experiment, miR-494 could relieve cerebral ischemia injury through inhibiting cyclin-dependent kinase 6(CDK6), ubiquitin-conjugating enzyme E2L6 (UBE2L6) and histone deacetylase 3 (HDAC3), which suggested that miR-494 might play an important role in the regulation of cell cycle following cerebral ischemia. This project intends to verify the following hypothesis:①miR-494 suppresses CDK6, and/or fibroblast growth factor16(FGF16)-Ras-extracellular signal-regulated kinase(ERK)--v-myc avian myelocytomatosis viral oncogene homolog(MYC) pathway, and/or phosphatase and tensin homolog(PTEN)-/protein kinase B(AKT)-mechanistic target of rapamycin(mTOR)-S6k pathway;②miR-494 inhibits UBE2L6, upregulates the hypoxia-inducible factor 1 α(HIF-1α) expression in nerve cells, thereby increases the p21 and p27 protein levels and inhibits cyclin-dependent kinase2(CDK2)activity;③miR-494 represses HDAC3 and downregulates the cyclin-dependent kinase1(CDK1)protein level. These all mediate the cell cycle arrest of neurons and astrocytes, reduce the neuronal apoptosis and glial scar formation,promote the recovery of neurological function and provide new targets for the treatment of ischemic stroke.

Conditions

Interventions

TypeNameDescription
OTHERThere is no intervention at all.There is no intervention at all.

Timeline

Start date
2018-06-06
Primary completion
2021-12-01
Completion
2021-12-01
First posted
2018-07-05
Last updated
2018-07-05

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03577093. Inclusion in this directory is not an endorsement.